Project 1: Reduction of Pro-Inflammatory Signaling
项目 1:减少促炎症信号传导
基本信息
- 批准号:10684082
- 负责人:
- 金额:$ 49.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAdultAdverse effectsAlzheimer&aposs disease modelAnimalsAnti-Inflammatory AgentsAstrocytesAtropineAttenuatedBehaviorBehavior assessmentBenzodiazepinesBiological MarkersBloodBlood brain barrier dysfunctionBrainBrain regionChemicalsChronicClinicalCognitiveCognitive deficitsCollaborationsConvulsantsCoxibsCyclic AMPDataDevelopmentDoseElectroencephalographyEnzyme InhibitionEpilepsyEpileptogenesisEpoxide hydrolaseFDA approvedFaceFemaleGliosisGoalsHMGB1 geneHistologyHomologous GeneHumanIL8 geneImpaired cognitionIncidenceIndividualInflammationInflammation MediatorsInflammatoryInflammatory ResponseInterleukin-1 ReceptorsInterleukin-1 betaInterleukin-6IntoxicationIsoflurophateLaboratoriesLeadLifeLinkMagnetic Resonance ImagingMeasuresMedical ResearchMemory LossMicrogliaMinocyclineModelingMonitorMorbidity - disease rateMotorNatural HistoryNerve DegenerationNeurologicNeurologic DeficitNeurological outcomeOrganophosphatesOutcomeOximesParkinson DiseasePathologyPathway interactionsPharmaceutical PreparationsPhenotypePilocarpinePositron-Emission TomographyPre-Clinical ModelProstaglandinsRattusRecurrenceResearch InstituteResolutionRestRiskSTAT3 geneSafetySeizuresSignal TransductionSignaling MoleculeSomanStatus EpilepticusStrokeSurvivorsTestingTherapeuticTreatment Efficacyacute careanakinraantagonistastrogliosischemical threatcognitive functioncyclooxygenase 2improvedin vivo imaginglipid mediatorlipidomemalemedical countermeasuremineralizationneuroinflammationneuropathologyneuroprotectionnovel therapeuticspredictive markerpreventresponsesmall molecule inhibitorspatiotemporalstandard of caretherapeutic candidatetherapeutic target
项目摘要
Project Summary – Project 1
Convulsant chemical threat agents, such as the organophosphates (OPs) diisopropylfluorophosphate (DFP) and
soman, can trigger seizures that progress to life-threatening status epilepticus (SE). Survivors face significant,
long-term morbidity, including spontaneous recurrent seizures (SRS) and mild-to-severe memory loss. Current
medical countermeasures fail to sufficiently protect against these long-term neurological deficits. Project 1 will
use a well-established rat model of acute DFP intoxication to test the hypothesis that therapies that promote
resolution of inflammation when administered as adjuncts to standard of care will mitigate the long-term, adverse
neurological consequences of acute OP intoxication. The scientific premise for this hypothesis includes
experimental evidence that: (1) acute OP intoxication triggers a robust neuroinflammatory response in multiple
brain regions that persists for up to 6 months; and (2) pro-inflammatory signaling is causally linked to
epileptogenesis and cognitive dysfunction in non-OP models. We will focus our initial efforts on lipid mediators
of inflammation. Our analyses of the brain lipidome in rats acutely intoxicated with DFP suggests two potential
therapeutic approaches: inhibiting cyclooxygenase-2 (COX-2) to block the formation of prostaglandins, and
inhibiting the enzyme soluble epoxide hydrolase (sEH) to stabilize anti-inflammatory lipid mediators. A small
molecule inhibitor of sEH (sEHI) developed at UC Davis has been shown to significantly attenuate SRS in
preclinical models of pilocarpine-induced epilepsy, improve cognitive function in preclinical models of Alzheimer’s
disease (AD), and reduce pathology in models of AD, stroke and Parkinson’s disease. Our preliminary data
suggest that sEHI also mitigates neuroinflammation and terminates SRS in the rat DFP model. Our goals are to:
(1) Characterize the spatiotemporal profile of neuroinflammation in male and female rats following acute DFP
intoxication in order to identify therapeutic targets, determine therapeutic windows, and develop translatable
biomarkers of inflammation that predict SRS and/or cognitive dysfunction. (2) Evaluate the neuroprotective
efficacy of sEHI and other compounds that target dysregulated inflammatory mediators in male and female rats
acutely intoxicated with DFP. (3) Determine the safety of therapeutic lead(s) and their efficacy in protecting
against adverse neurological consequences in a rat model of acute soman intoxication. If successful, Project 1
will identify novel therapeutic lead(s) that improve long-term neurological outcomes when used as adjuncts to
standard of care, as well as biomarkers that identify individuals at increased risk for developing SRS and/or
cognitive deficits following acute OP intoxication.
项目摘要-项目1
惊厥性化学威胁剂,如有机磷酸盐(OP)二异丙基氟磷酸盐(DFP)和
梭曼可引发癫痫发作,发展为危及生命的癫痫持续状态(SE)。幸存者面临着重大的,
长期发病率,包括自发性复发性癫痫发作(SRS)和轻度至重度记忆丧失。电流
医疗对策不能充分防止这些长期的神经缺陷。项目1将
使用一个成熟的急性DFP中毒大鼠模型来检验促进DFP中毒的治疗的假设。
当作为标准治疗的替代品给药时,炎症的消退将减轻长期的不良反应,
急性OP中毒的神经学后果。这一假设的科学前提包括
实验证据表明:(1)急性OP中毒引发了多个神经系统的强烈神经炎症反应,
持续长达6个月的大脑区域;和(2)促炎信号与
癫痫发生和认知功能障碍。我们将集中我们的初步努力,脂质介质
炎症。我们对DFP急性中毒大鼠脑脂质组的分析表明,
治疗方法:抑制环氧合酶-2(考克斯-2)以阻断胡萝卜素的形成,和
抑制可溶性环氧化物水解酶(sEH)以稳定抗炎脂质介质。一个小
加州大学戴维斯分校开发的sEH分子抑制剂(sEHI)已显示出显著减弱
毛果芸香碱诱导癫痫的临床前模型,改善阿尔茨海默病临床前模型的认知功能
疾病(AD),并减少AD、中风和帕金森病模型中的病理学。我们的初步数据
表明sEHI也减轻神经炎症并终止大鼠DFP模型中的SRS。我们的目标是:
(1)描述急性DFP后雄性和雌性大鼠神经炎症的时空特征
中毒,以确定治疗目标,确定治疗窗口,并开发可翻译的
预测SRS和/或认知功能障碍的炎症生物标志物。(2)评估神经保护
在雄性和雌性大鼠中sEHI和其它靶向失调的炎症介质的化合物的功效
急性中毒(3)确定治疗电极导线的安全性及其在保护
对抗急性梭曼中毒大鼠模型中的不良神经学后果。如果成功,项目1
将确定新型治疗电极导线,用于治疗时可改善长期神经学结局,
护理标准,以及识别发生SRS和/或SRS风险增加的个体的生物标志物
急性OP中毒后的认知功能障碍。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pamela J Lein其他文献
Pamela J Lein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pamela J Lein', 18)}}的其他基金
Ketogenic diet approaches to slow disease progression in a rat model of Alzheimer's disease
生酮饮食方法可减缓阿尔茨海默病大鼠模型的疾病进展
- 批准号:
9977496 - 财政年份:2020
- 资助金额:
$ 49.11万 - 项目类别:
Identifying Molecular Targets for the Proconvulsant Activity of TETS
确定 TETS 促惊厥活性的分子靶点
- 批准号:
9905564 - 财政年份:2019
- 资助金额:
$ 49.11万 - 项目类别:
Does air pollution increase risk of AD in a genetically susceptible animal model?
空气污染是否会增加遗传易感动物模型患 AD 的风险?
- 批准号:
9126737 - 财政年份:2016
- 资助金额:
$ 49.11万 - 项目类别:
Mitigation of Neurological Damage Following Seizures
减轻癫痫发作后的神经损伤
- 批准号:
10204125 - 财政年份:2012
- 资助金额:
$ 49.11万 - 项目类别:
Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication
针对 TETS 和 OP 中毒的新型抗惊厥和神经保护疗法
- 批准号:
10204117 - 财政年份:2012
- 资助金额:
$ 49.11万 - 项目类别:
Novel anticonvulsant and neuroprotective therapies for TETS and OP intoxication
针对 TETS 和 OP 中毒的新型抗惊厥药和神经保护疗法
- 批准号:
9142832 - 财政年份:2012
- 资助金额:
$ 49.11万 - 项目类别:
Novel anticonvulsant and neuroprotective therapies for TETS and OP intoxication
针对 TETS 和 OP 中毒的新型抗惊厥药和神经保护疗法
- 批准号:
8925299 - 财政年份:2012
- 资助金额:
$ 49.11万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 49.11万 - 项目类别:
Research Grant